Skip to main content
EDSA
NASDAQ Life Sciences

$12M Upfront, Up to $134M Milestones: Kyorin Licenses Edesa's ARDS Drug for Japan

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.528
Mkt Cap
$28.915M
52W Low
$0.72
52W High
$20.32
52W Position info
251% above low
Off High info
88% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

EDSA has more than doubled off its 52-week low of $0.72.

Summary

Edesa signed an exclusive Japan development and commercialization deal with Kyorin Pharmaceutical for paridiprubart in ARDS. Edesa gets $12 million upfront, up to roughly $134 million in development, regulatory and sales milestones, and tiered double-digit royalties on Japanese net sales; Kyorin funds the Japan development and commercialization work and Edesa supplies the product. The cash matters immediately: the Q3 10-Q carried a going concern warning that current resources would not fund operations through fiscal 2026, and this upfront is a meaningful chunk of a company with a market cap under $30 million. It also validates the asset — paridiprubart showed a statistically significant 28-day mortality benefit in a Phase 3 ARDS study (39% versus 52% adjusted mortality risk, p<0.001) — and brings in a partner with a respiratory sales footprint in one of the world's largest pharma markets. Edesa keeps all rights outside Japan, and Kyorin holds a right of first negotiation for acute kidney injury. Watch for the U.S. government-funded ARDS platform study readout and the EB06 vitiligo Phase 2 enrollment that the October FDA IND clearance enabled.

At the time of this announcement, EDSA was trading at $2.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.9M. The 52-week trading range was $0.72 to $20.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

EDSA - Latest Insights

EDSA
Nov 09, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.35
Real-time Price: $2.66 info
Change: +$0.310 (+13%) info
Market Cap: $28.915M info
EDSA
Oct 23, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.77
Real-time Price: $2.66 info
Change: -$0.110 (-4%) info
Market Cap: $28.915M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $2.66 info
Change: +$0.040 (+2%) info
Market Cap: $28.915M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.84
Real-time Price: $2.66 info
Change: -$0.180 (-6%) info
Market Cap: $28.915M info
EDSA
Aug 25, 2026, 4:38 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $2.66 info
Change: -$1.79 (-40%) info
Market Cap: $28.915M info